U.S. Markets closed

Call of the day: Tilray as Benchmark starts coverage with bullish rating

Benchmark initiated its coverage of Tilray with a 'buy' rating and a $200 price target. Analyst Mike Hickey said he's bullish on the cannabis company's early leadership in the medical cannabis market in Canada and its strategic alliance with Novartis.